Media Releases - 2007

	Orchid receives US FDA approval for Cefpodoxime Proxetil ANDA
	Orchid’s Q2 FY08 revenue higher by 20% at Rs 295 crore Net profit jumps 115% to Rs 63 crore
	Orchid’s Managing Director honoured with Doctorate by leading university
	Orchid receives US FDA approval for its Cefdinir ANDAs Receives approval in about 12-months from filing
	Orchid’s Q1 FY 2007-08 net profit surges by 252% to Rs 51 crore Key product launches in the US market and foreign exchange gains drive strong profits
	Orchid receives US FDA approval for its Cefepime ANDA
	Orchid forays into the non-antibiotic generic formulations segment Receives tentative approval from US FDA for Terbinafine HCL Tablets ANDA
	Orchid’s turnover rises to Rs 934 crore during FY 2006-07 Net profit increases to Rs 97 crore
	Orchid’s drug discovery subsidiary (Orchid Research Labs) awarded Partner of Choice award by Frost & Sullivan
	Orchid to foray into the Canadian generic formulations market Receives Canadian TPD approval for two generic formulations
	Orchid raises USD 200 million by way of zero coupon FCCBs
	Orchid in a new licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe
	Orchid’s Betalactam API facility at Aurangabad approved by the UK MHRA Will support European generic foray
	Orchid registers turnover of Rs 239 crore during Q3 FY 2006-07 Net profit stands at Rs 28 crore